康哲药业(00867.HK) 公布,集团自主研发的创新药CMS-D005注射液获中国国家药品监督管理局签发药物临床试验批准,同意集团在内地健康以及超重和肥胖成人受试者中开展评价CMS-D005安全性、耐受性及药代动力学和药效学特征的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-27 16:25。)AASTOCKS新闻
Source Link康哲药业(00867.HK) 公布,集团自主研发的创新药CMS-D005注射液获中国国家药品监督管理局签发药物临床试验批准,同意集团在内地健康以及超重和肥胖成人受试者中开展评价CMS-D005安全性、耐受性及药代动力学和药效学特征的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-27 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.